An observational study in Oligomenorrhea, Amenorrhea and Polycystic Ovary Syndrome (PCOS), sponsored by Cornell University. Completed at 1 site in United States. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-09.
Sponsored by Cornell University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Amenorrhea with a site in United States — 7 open to participants now, 9 under way, 1 of them phase 3. Amenorrhea · United States.
Among the 43 studies in Amenorrhea with a site in United States, this one is the 10th largest by enrollment of the 13 observational ones that give a count, is one of 2 that started in 2011, is one of 13 observational ones, and was the 23rd registered.
80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.
Browse Amenorrhea studies →7 of the 43 studies in Amenorrhea with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–40 · Women only
University of Virginia · Sites in United States
Ages 14–30 · Women only
Massachusetts General Hospital · Sites in United States
Ages 14–30 · Women only
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 8–99
University of Colorado, Colorado Springs · Sites in United States
Ages 18–35 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Amenorrhea studies recruiting now, none (0%) set no upper age limit and 11 (85%) stop at 75 or younger; 8 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 35 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 6 · Phase 4 2
First in 1989; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 73 is below the median of 85 across 26 observational studies indexed under Amenorrhea.
Median enrollment 37 across the 30 interventional studies, 111 across the 13 observational. Of the 28 that completed or were terminated, 13 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 43 have an industry lead sponsor. The 10 most frequent:
Cornell University is the lead sponsor of 103 studies on the registry; 16 are open to participants now.
Cornell University has 3 studies filed under Amenorrhea — fewer than ten, so there is no comparison to draw.
2 of the studies in Amenorrhea with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00589654Memorial Sloan Kettering Cancer CenterMenstrual Cycle Maintenance and Quality of Life: A Prospective Study | 2026-12 |
| NCT05629377Mayo ClinicHypothalamic Amenorrhea as a Fertility Status Marker for Cardiovascular Health (ARCH) | 2026-12-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies in Amenorrhea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In women with regular menstrual cycles, antral follicles have been shown to grow in synchronous cohorts, called waves, 2-3 times in a menstrual cycle. It is unknown whether these waves of follicle growth also occur in women with amenorrhea or if there is abnormal/absent follicle growth. Further, oligo- or amenorrhea has been associated with metabolic disturbances, such as over- or under-nutrition, central obesity and insulin resistance. Yet, mechanisms whereby metabolic factors influence folliculogenesis in women are poorly understood. To understand potential mechanisms, the investigators plan to characterize follicle growth dynamics in women with or without regular menstrual cycles and identifying key metabolic differences in these women which may be important in normal follicle development and fertility.
In the ovaries, eggs rest in fluid filled sacs called follicles. When follicles grow they form small fluid-filled cysts that can be easily seen when we use ultrasound to view the ovaries. In women with regular menstrual cycles, groups of 10 to 20 follicles grow and regress at 2 or 3 different times during their cycle (usually over a 28- day period). Several of these follicles grow to a stage where they begin to develop the potential to ovulate - but in general only one follicle is chosen to ovulate. Thus, at any given time during the menstrual cycle, numerous fluid-filled follicles can be visualized in a woman's ovaries at various stages of development using transvaginal ultrasonography. In women with absent or infrequent menstrual cycles, very little is known about the growth patterns of their follicles and how factors such as metabolic hormones, might play a role in the failure to ovulate. Being underweight or overweight increases your chances of having irregular or absent menstrual cycles and that a history of abnormal reproductive function compounds a woman's risk for chronic diseases such as infertility, diabetes, hypertension, atherosclerosis and certain cancers. This is particularly the case for women with polycystic ovary syndrome (PCOS) that have menstrual cycles that appear to worsen or improve depending on their body weight and metabolic status. PCOS is an endocrine disorder that affects 6-12% of reproductive-aged women within the general population. The hallmark features of PCOS are menstrual irregularity, increased levels of androgens, and polycystic ovaries. The current diagnostic criteria require 2 out of 3 of these features to be present for the diagnosis, therefore a number of phenotypes of PCOS exist. However, the metabolic and reproductive differences across the phenotypic spectrum of PCOS are not well understood. Women with PCOS characteristically have polycystic ovaries, where up to 10 times more follicles are present in the ovary at any given time. Further, the follicle-size populations and overall distribution throughout the ovary varies in women - follicles may be situated around the periphery of the ovary or may be distributed throughout the ovary. Presumably these small follicles are arrested in development - but emerging data from the Lujan laboratory suggest that this is not the case. It is assumed that ovulation does not occur and that follicles do not grow in a normal wave pattern. In truth, no study has ever looked to see whether follicles are actually growing, regressing or are arrested in women with irregular/absent menstrual cycles. By comparing follicle wave dynamics, reproductive hormones and markers of metabolism in women with regular and irregular menstrual cycles, the researchers plan to identify what factors might explain why fertility potential and long-term health are compromised in some women but not in others. Further, we will determine if any of these metabolic factors are unique to PCOS representing specific metabolic risks or follicle growth impairment. The ultimate goal of this research is to understand how body composition, nutrition and metabolism regulate follicle development in women so we can better develop lifestyle and drug therapies to help women preserve their fertility and long-term health. Since obesity has recently become the leading cause of infertility in North America, these studies are especially important.
To accomplish our objective, the investigators plan to recruit up to 40 women with regular menstrual cycles and up to 40 women with irregular/absent menstrual cycles. Our goal is to recruit an equal number of women in each group such that they are matched for age (18 - 35 years old) and body mass index (BMI; Normal weight = 18 - 24 kg/m2; Overweight = 25 - 29 kg/m2; Obese = 30kg/m2). Women will undergo serial ultrasonographic of their ovaries every other day from ovulation to ovulation in women with regular menstrual cycles or for 5 weeks in women with cycle irregularity. Blood samples will be collected at each visit. Ultrasound scans of the ovaries will be assessed for the total number, size, and distribution of follicles using ultrasound imaging techniques. Blood samples collected will be assayed to determine serum concentrations of luteinizing hormone (LH), follicle stimulating hormone (FSH), estradiol, progesterone, anti-müllerian hormone (AMH), and inhibin B. During day 3-5 in women with regular menstrual cycles or at a time where no dominant follicle or corpus luteum is present, an early morning visit will be conducted to assess the following metabolic parameters : (1) 75-gram oral glucose tolerance test to characterize glucose and insulin dynamics at 0, 30, 60, 90, and 120 minutes post-glucose ingestion; (2) dual X-ray absorptiometry (DXA) scan to quantify body fat and lean muscle distribution; (3) vitals and anthropometry assessment to measure waist and hip circumference, height, weight, blood pressure, and heart rate, and (4) fasting blood tests to detect serum concentrations of androgens (i.e., total testosterone, androstenedione, free androgen index) and serum markers of metabolic syndrome (i.e., lipids and hemoglobin A1C); (5) optional subcutaneous fat biopsy to analyze fat cells, which represent a site of reproductive hormone synthesis.
Women must be able to transport to Cornell University in Ithaca, NY. Eligible participants are between 18-35 years with a BMI of 18 kg/m2 or higher. Women are screened and enrolled following consent based on their response to our advertisements. Enrollment is restricted to the geographical area.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Either:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult women will be assigned to this category if they report a history of regular menstrual cycles.
Adult women will be assigned to this category if they report a history of irregular menstrual cycles, including women with a pre-existing diagnosis of PCOS.
Follicle number
The number of all antral follicles in each ovary will be determined using ultrasonography for each participant. Changes in follicle number over time will be compared between groups.
Time frame: 4-5 weeks
Follicle diameter
The diameter of all follicles \>2mm will be determined using ultrasonography for each participant. Changes in follicle diameter over time will be compared between groups.
Time frame: 4-5 weeks
Ovarian Volume
The size of each ovary will be determined using ultrasonography for each participant during study participation and compared between groups.
Time frame: 4-5 weeks
Anti-Müllerian hormone
The serum AMH concentration will be determined during study participation and assessed in association with the change in follicle number, diameter and between groups.
Time frame: 4-5 weeks
Serum FSH concentration
The serum FSH concentration will be determined during study participation and assessed in association with the change in follicle number, diameter and between groups.
Time frame: 4-5 weeks
Serum LH concentration
The serum FSH concentration will be determined during study participation and assessed in association with the change in follicle number, diameter and between groups.
Time frame: 4-5 weeks
Serum progesterone concentration
The serum progesterone concentration will be determined during study participation, assessed in association with luteal dynamics and compared between groups.
Time frame: 4-5 weeks
LH-FSH ratio
The ratio of circulating LH to FSH concentrations will be determined for each participant and compared between groups.
Time frame: 4-5 weeks
Insulin sensitivity
Insulin sensitivity will be determined by administration of an oral glucose tolerance test and compared between groups.
Time frame: 1 day
Androgen concentrations
Total testosterone, androstenedione and free androgen index concentrations in serum will be determined and compared between groups.
Time frame: 1 day
Menstrual Cycle Length
Average menstrual cycle length as determined by self-reported history and the menstrual cycle length during study participation will be determined and compared between groups.
Time frame: 4-5 weeks
Hirsutism
Degree of hirsutism as judged by the Ferriman-Gallwey scale will be determined and compared between groups.
Time frame: 1 day
Serum markers of metabolic syndrome
Lipids, glucose and HbA1C concentrations will be determined and compared between groups.
Time frame: 1 day
Blood Pressure
Blood pressure will be determined and compared between groups.
Time frame: 1 day
Body mass index
The ratio of weight to height will be determined and compared between groups.
Time frame: 1 day
Waist-to-hip ratio
The ratio of waist circumference to hip circumference will be determined and compared between groups.
Time frame: 1 day
Body fat distribution
Percentage and distribution of fat and lean mass as assessed using DXA technology will be compared between groups.
Time frame: 1 day
Subcutaneous fat biopsy (optional)
Fat cells, representing an important site of reproductive hormone production, will be compared between groups.
Time frame: 1 day
The record gives a start of Sep 2011, a primary completion of Sep 2021 and a completion of Sep 2021. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.